REGENXBIO (RGNX) has an average rating of overweight and mean price target of $26.25, according to analysts polled by FactSet.
What else is happening in Research?
Research
Barrington Upgrades LeMaitre Vascular to Outperform From Market Perform, Price Target is $95
LeMaitre Vascular (LMAT) has an average rating of overweight and mean price target of $116.25, according to analysts polled by FactSet.
$LMAT
Research
JP Morgan Downgrades Smith & Nephew to Neutral, Reduces PT
JP Morgan on Wednesday downgraded medical technology company Smith & Nephew (SN.L) to neutral from overweight and lowered the price target to 12.90 pounds sterling from 14.38 pounds.
$SN.L
Research
DZ Bank AG Research Upgrades Zalando to Buy, Boosts PT
DZ Bank AG Research on Wednesday upgraded German online retailer Zalando (ZAL.F) to buy from hold and raised its price target to 38 euros from 27 euros.
$ZAL.F